NDAC Member Resigns Over Plan B, Rallies Fellow Panelists To Action
This article was originally published in The Pink Sheet Daily
Executive Summary
Former panel member and consultant says he will pursue options such as organizing a group letter to a medical journal from advisory committee members protesting FDA’s postponement of the Plan B decision.
You may also be interested in...
FDA Women’s Health Director Resigns Over Plan B
Susan Wood says she can “no longer serve as staff when scientific and clinical evidence...has been overruled.”
FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs
Agency initiates advance notice of proposed rulemaking to determine whether an active drug ingredient can be marketed both Rx and OTC for the same indication.
Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products
FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation